Clinical Trials Logo

Arteriovenous Fistula clinical trials

View clinical trials related to Arteriovenous Fistula.

Filter by:

NCT ID: NCT03366727 Completed - Clinical trials for Arteriovenous Fistula Stenosis

AcoArt III / Arterio-venous Fistula in China

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

This trial is aimed to evaluate the safety and efficacy of DCB in treating AVF stenosis in chinese population.

NCT ID: NCT03355508 Recruiting - Clinical trials for Arterio-venous Fistula, Puncture, Chronic Desease

Impact of the Arteriovenous Fistula Puncture Technique On the Hemodialysis Session For Patient and Caregiver

Start date: September 29, 2017
Phase: N/A
Study type: Interventional

40000 patients are hemodialysis each year in France . In the case of chronic care, 78% of patients have an arteriovenous fistula. In order to perform the hemodialysis session, 2 techniques of puncture of the fistula are possible: - Bevel puncture upwards then flipping the needle - or puncture bevel down. At present, there is no consensus or study on the technique of puncture fistula which generates different professional practices.

NCT ID: NCT03317821 Completed - Clinical trials for Dural Arteriovenous Fistula

PHIL Evaluation in the Endovascular Treatment of Intracranial Dural AVF

Start date: September 18, 2017
Phase:
Study type: Observational [Patient Registry]

The primary objective of this study is to demonstrate the safety and efficacy of the PHIL® liquid in endovascular treatment of dural arteriovenous fistula.

NCT ID: NCT03311581 Completed - Clinical trials for End Stage Renal Disease

The Feasibility of Propofol TCI in Hemodialysis Patients Undergoing Arteriovenous Shunt Surgery

Start date: September 11, 2017
Phase: Phase 1
Study type: Interventional

Written informed consent must be obtained before any study specific procedures are undertaken. Informed consent will be obtained during pre-operative assessment.

NCT ID: NCT03246984 Completed - Kidney Diseases Clinical Trials

VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ

VALUE
Start date: September 7, 2017
Phase: N/A
Study type: Interventional

This is a prospective single arm study enrolling patients who are scheduled for creation of a new Brachiocephalic or Radiocephalic AV fistula. Up to 80 patients will be enrolled, 50 with upper arm AV fistula and 30 with forearm AV fistula. All patients will be implanted with the VasQ device, a subcutaneous arteriovenous conduit support for vascular access. The follow up period in this study will be for a duration of 12 months, with follow up visits scheduled at 1, 3, 6, 9, and 12 months.

NCT ID: NCT03245944 Completed - Clinical trials for Immature Arteriovenous Fistula

Optimal Timing of Percutaneous Intervention in Non-maturing Dialysis Fistulas

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

Arteriovenous fistulas (AVFs) are the preferred type of vascular access for dialysis, but many of them fail to mature. The optimal timing of intervention to salvage immature AVFs is unknown.The study proposes a randomized clinical trial comparing the clinical and economic impact of early vs late angioplasty in non-maturing AVFs. The study proposes a RCT to test the hypothesis that, as compared to early angioplasty of non-maturing AVFs, late angioplasty results in a lower proportion of AVFs being used at 6 months, but a greater long-term AVF patency , lower requirement of subsequent interventions to maintain AVF patency for dialysis, and lower overall cost of access maintenance.

NCT ID: NCT03242343 Completed - Diabetes Mellitus Clinical Trials

VasQ External Support for Arteriovenous Fistula

Start date: November 29, 2017
Phase: N/A
Study type: Interventional

This is a prospective clinical study of the VasQ external support for arteriovenous fistulas. The device is designed to improve fistula outcomes by optimizing the geometrical configuration of the fistula, influencing hemodynamics, minimizing turbulence and promote laminar flow. All patients will be implanted with the VasQ device and will be followed up for a duration of 24 months.

NCT ID: NCT03231410 Recruiting - Clinical trials for End Stage Renal Disease

Role of Monocytes Adhesion and Vascular Lesions in Vascular Access Success or Failure in Uremic Patients

ROMAVAS
Start date: January 2017
Phase:
Study type: Observational

This study is designed to identify novel predictors of vascular access success or failure in chronic kidney disease patients. Despite efforts to improve placement of arteriovenous fistula (AVF) the primary failure rates are reported as high as 20-50%, but standard tools like ultrasound cannot inform the clinician sufficiently to accurately predict success or failure. The aim of this study is to perform enhanced assessments of arterial health preoperatively and correlate these measurements with vascular lesions (microscopic tissue changes and monocyte infiltration) and early AVF outcome. Activation of monocytes in uremia condition is responsible for endothelium dysfunction, intimal hyperplasia and atherosclerosis. The investigators expect that stiff arteries caused by monocyte dysfunction refer to the poor distensability and probably longer maturation time.

NCT ID: NCT03213756 Completed - Clinical trials for Arteriovenous Fistula Stenosis

Isometric Preoperative Exercise on Autologous Arteriovenous Fistulas. Randomized Clinical Trial

PHYSICALFAV
Start date: July 18, 2017
Phase: N/A
Study type: Interventional

A good vascular access (VA) is vital for hemodialysis (HD) patients. The start of HD with autologous arteriovenous fistula (AVF) means higher survival, lower sanitary costs and complications. The distal forearm AVF is known as the best option but not all patients are good candidates for this surgery, and there is a primary failure rate between 20 and 50% published in literature. The choice of the optimal AVF for each patient is conditioned mainly by the anatomical and hemodynamic characteristics of the artery and the vein chosen to perform the anastomosis. These characteristics can be modified by performing physical exercise Some vascular access guidelines suggest the performance of isometric exercises in the pre and postoperative period of the AVF confection. However, there is very little data in literature on the possible efficacy of preoperative exercise, although small published observational studies point to an improvement in the venous and arterial caliber. Regarding the postoperative exercises, they do seem to improve maturation, however the degree of evidence in literature is low and there is no consensus on the exercise protocol to follow. We present an open-label, multicenter, prospective, controlled and randomized study in order to evaluate the usefulness of preoperative isometric exercise (PIE) in pre-dialysis patients or in prevalent HD with indication of performing a new AVF. The randomization will be 1: 1, one group of patients will perform PIE for 8 weeks and the other group of patients will be a control group. The main purpose will be to evaluate if there is a lower rate of primary failure in the PIE group compared with control group.

NCT ID: NCT03192800 Recruiting - Clinical trials for Spinal Vascular Disorder Nos

Clinical Outcome in Patients With Spinal Dural Arteriovenous Fistulas (COPSDAVF)

COPSDAVF
Start date: March 1, 2013
Phase:
Study type: Observational

Spinal dural arteriovenous fistulas (SDAVFs) are the most common vascular disorder of the spine and account for approximately 70% of spinal vascular malformation.They are a rare pathology with an excepted incidence of only 5-10 new cases per million inhabitants per year. Most fistulas are found in the thoracolumbar region and > 80% of all SDAVFs are located between T6 and L2, whereas the cranio-cervical, cervical and sacral fistulas are more rare. SDAVFs have an overwhelmingly male predominance (80%), with an age presentation in the fifth or sixth dacede. It is presumed that SDAVFs are acquired diseases. A typical SDAVF is located inside the dural mater close to nerve root. It is fed by a radiculomeningeal artery and enters a radicular vein that merges in the perimedullary plexus. The presence of a shunt leads to a reversal of blood flow to the spinal cord venous system, which then induces venous hypertensive myelopathy.